📞 (430) 288-5800 · 100 Independence Pl, Suite 405 · Tyler, TX 75703 · Mon–Fri 9am–5pm
Bipolar Disorder · Medication

Bipolar Disorder Medications: What Each One Does and How Providers Choose

Bipolar disorder has a wider range of effective medication options than almost any other psychiatric condition — and the differences between them matter significantly for individual patients. Understanding how providers choose between mood stabilizers changes how patients participate in these decisions.

Published 13 August 2026East Texas Psychiatry & Counseling9 min read
In crisis? If you are thinking about harming yourself, Call (430) 288-5800988 Suicide & Crisis Lifeline, or Call (430) 288-5800911 or go to your nearest emergency room. Help is available 24/7.

Quick answer

Bipolar disorder medication includes lithium, valproate, lamotrigine, and atypical antipsychotics, each with different evidence for mania, depression, and maintenance. Lithium has the strongest overall evidence and uniquely reduces suicide risk. Lamotrigine is preferred for depression-predominant presentations.

A provider explaining bipolar disorder medication options to a newly diagnosed patient
Choosing the right mood stabilizer requires understanding evidence, episode type, and individual factors.

Lithium: The Gold Standard

Lithium is the oldest, most studied, and most broadly effective mood stabilizer for bipolar disorder, and it remains the first-line agent against which all others are compared. Its mechanism of action is incompletely understood but involves modulation of multiple signaling pathways including glycogen synthase kinase-3 (GSK-3) inhibition, inositol depletion, neuroprotective effects, and possibly direct effects on circadian rhythm regulation. What is understood is its clinical effectiveness: more than 60 years of evidence documents lithium’s efficacy for acute mania, prophylaxis against both manic and depressive episodes, and — uniquely among mood stabilizers — a specific anti-suicide effect. Randomized trials and observational studies consistently find that lithium treatment reduces suicide rates in bipolar disorder by approximately 60% compared to no lithium, an effect not demonstrated to the same degree by any other mood stabilizer. For this reason alone, lithium is the preferred agent for patients with significant suicide risk.

Lithium requires serum level monitoring because the therapeutic window is relatively narrow — effective levels are typically 0.6–1.2 mEq/L, and toxicity begins at levels above 1.5 mEq/L. Blood draws for lithium levels, kidney function (lithium affects renal concentrating ability and can cause long-term kidney damage at high levels in some patients), and thyroid function (lithium commonly causes hypothyroidism, which is easily treated but requires monitoring) are part of the ongoing management protocol. These monitoring requirements are not optional; they are the mechanism by which long-term lithium use is made safe. Common side effects include tremor (often manageable with dose adjustment or low-dose propranolol), cognitive blunting at higher doses, polyuria and polydipsia, and weight gain. Patients who tolerate and maintain therapeutic lithium levels have substantially better long-term outcomes than those on any other single mood stabilizer.

Valproate, Lamotrigine, and Atypical Antipsychotics

Valproate (brand names Depakote, Depakene) is the second most commonly used mood stabilizer for bipolar disorder and the most effective agent for acute mania, mixed states, and rapid cycling. It works primarily through sodium channel modulation and enhancement of GABA activity. Its onset for acute mania is faster than lithium, making it particularly useful in inpatient or acute settings. Valproate also requires laboratory monitoring including serum levels and liver function tests. Side effects include weight gain, sedation, hair thinning, tremor, and — critically — significant teratogenicity (fetal harm including neural tube defects and neurodevelopmental effects) that makes it contraindicated in women of childbearing potential in most clinical guidelines unless alternative options have failed and effective contraception is used. Polycystic ovarian syndrome is also associated with valproate use in women and requires monitoring.

Lamotrigine (Lamictal) has its strongest evidence for bipolar depression maintenance and is the preferred mood stabilizer for depression-predominant bipolar disorder presentations, including most people with Bipolar II. Unlike lithium and valproate, lamotrigine has limited efficacy for acute mania but is highly effective at preventing future depressive episodes. Its key safety concern is the rare but serious Stevens-Johnson syndrome (SJS), a potentially life-threatening skin reaction that is entirely preventable through slow, correct dose titration. Lamotrigine must be started at a very low dose (typically 25 mg/day for the first two weeks) and increased gradually over 6–8 weeks to target dose. Rushing the titration significantly elevates SJS risk; the slow titration schedule is non-negotiable.

Atypical antipsychotics with mood stabilizing evidence include quetiapine, lurasidone, olanzapine, aripiprazole, asenapine, and cariprazine, among others. Quetiapine has evidence for both acute mania and bipolar depression and is one of the most commonly prescribed agents for bipolar disorder. Lurasidone has specific evidence for bipolar depression with a favorable metabolic side effect profile. Olanzapine is effective for mania but carries significant weight gain and metabolic risk that limits its long-term use. Cariprazine has evidence for both phases with a mechanism (D3/D2 partial agonism) that may have particular relevance for bipolar depression.

A patient and provider reviewing bipolar medication response at a follow-up appointment
Medication selection for bipolar disorder is an ongoing clinical process calibrated to response and tolerability over time.

How Providers Choose Between Them

The medication selection process for bipolar disorder is individualized rather than algorithmic, but several key clinical factors consistently guide the decision. Episode type predominance is the first consideration: mania-predominant presentations are best addressed by agents with strong antimanic evidence (lithium, valproate, quetiapine); depression-predominant presentations Call (430) 288-5800

Suicide risk significantly influences medication selection: lithium is the preferred agent when suicide risk is elevated, given its unique anti-suicide evidence. Gender and reproductive status: valproate is generally avoided in women who may become pregnant; lamotrigine requires careful titration but has a more favorable reproductive safety profile. Medical comorbidities: lithium is avoided in severe kidney disease; valproate is avoided in liver disease; atypical antipsychotics with significant metabolic effects are used cautiously in patients with diabetes or significant cardiovascular risk. Prior medication history is always reviewed: a medication that did not work previously at adequate dose may not be worth retrying; one that produced excellent response but was stopped for a non-efficacy reason may be worth returning to.

Pharmacogenomic testing — analysis of genetic variants that affect drug metabolism — is increasingly available and can help predict which medications will be most effectively metabolized and which may produce predictable adverse reactions, though its clinical utility for bipolar disorder is still developing compared to its more established role in antidepressant selection.

Starting Medication and What to Expect

Starting a mood stabilizer is a commitment to ongoing medication management, not a trial to be abandoned if full response does not appear within days. Lithium and lamotrigine require weeks to months to reach therapeutic dose and produce their full prophylactic benefit. Valproate acts faster for acute mania. Atypical antipsychotics often produce partial response within days at acute doses. Whatever the starting agent, follow-up at 2–4 weeks is essential for laboratory monitoring where indicated, dose adjustment, side effect assessment, and clinical response evaluation.

Stopping a mood stabilizer without provider guidance carries significant risk, including rapid rebound mania or depression that may be more severe than baseline. This is particularly true for lithium, where abrupt discontinuation is associated with a high risk of manic episode that may be refractory to lithium reinstatement. Any decision to stop or change medication should be made collaboratively with your provider, not unilaterally. Call (430) 288-5800schedule online for bipolar evaluation and medication management in Tyler and by telepsychiatry across Texas.

Key Takeaways

  • Lithium is the gold standard with the strongest evidence and unique suicide risk reduction — it requires monitoring
  • Lamotrigine is preferred for depression-predominant bipolar disorder but requires slow titration to prevent Stevens-Johnson syndrome
  • Valproate is most effective for acute mania and rapid cycling but is contraindicated in most pregnant women
  • Medication selection is individualized based on episode type, suicide risk, sex, medical history, and prior response

Frequently Asked Questions

Can I stop my mood stabilizer if I feel stable?

Feeling stable is evidence the medication is working. Stopping abruptly — particularly lithium — carries high risk of rapid relapse. Discuss any changes with your provider first.

Do I need blood tests on mood stabilizers?

Lithium and valproate require regular serum levels and organ function monitoring. Lamotrigine does not typically require serum monitoring. Your provider will specify the monitoring schedule for your specific medication.

Are mood stabilizers the same as antidepressants?

No. They are a distinct medication class. Antidepressants alone are generally not appropriate for bipolar disorder and may worsen cycling. Mood stabilizers address both poles of bipolar disorder.

How long will I take a mood stabilizer?

For most people with bipolar disorder, long-term or indefinite maintenance is appropriate given the high recurrence risk without it. The duration is determined by your risk profile and discussed with your provider.

Medical disclaimer. This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Individual results vary. Always consult a qualified healthcare provider. If you are in crisis, Call (430) 288-5800988 or Call (430) 288-5800911.

Reviewed by the clinical team at East Texas Psychiatry and Counseling — board-certified psychiatric nurse practitioners (PMHNPs) with more than 50 years of combined clinical experience, including U.S. Navy and critical-care backgrounds.

Vital Voice Online

Schedule a Consultation

Fill out the form below and we'll get back to you within 24 hours.

Request Sent!

We've received your request and will be in touch within 24 hours.

Something went wrong

SPRAVATO® Treatment at East Texas Psychiatry
Advanced Depression Care

Struggling with Treatment-Resistant Depression?

If traditional antidepressants haven't worked, SPRAVATO® (esketamine) nasal spray may be the breakthrough you've been waiting for. Experience a new path to healing in East Texas Psychiatry and Counseling.

Learn More About SPRAVATO®

Administered in our monitored, comfortable Tyler, TX clinic.